

# Contents

<b>Preface .....</b>	iii
<b>1. Executive Summary .....</b>	1
<b>2. Introduction .....</b>	7
<b>2.1 Overview .....</b>	7
<b>2.2 Purpose of this Report .....</b>	13
<b>2.3 Target Audiences of this Report .....</b>	14
<b>2.4 Scope of this Report .....</b>	14
<b>3. Background Information .....</b>	17
<b>3.1 Internal Deposition of Radionuclides .....</b>	17
<b>3.1.1 Inhalation .....</b>	18
<b>3.1.2 Ingestion .....</b>	20
<b>3.1.3 Absorption from Skin Contamination .....</b>	21
<b>3.1.4 Absorption Through Wounds .....</b>	21
<b>3.2 External Contamination .....</b>	22
<b>3.3 Effects of Weather .....</b>	22
<b>3.4 Complications Due to the Presence of Multiple Agents or Serious Injuries .....</b>	23
<b>3.5 Radiological Triage .....</b>	26
<b>3.6 Proximity to the Incident .....</b>	26
<b>3.7 Previous Experience with Internal Contamination .....</b>	27
<b>3.8 Conclusions .....</b>	28
<b>4. Settings in Which Persons May Become Contaminated with Radioactive Material .....</b>	29
<b>4.1 Radiological Dispersal Device .....</b>	29
<b>4.1.1 Incident Characteristics .....</b>	30
<b>4.1.2 Nature of Contamination .....</b>	30
<b>4.2 Aerosol Dispersal into a Public Area .....</b>	31
<b>4.2.1 Incident Characteristics .....</b>	31
<b>4.2.2 Nature of Contamination .....</b>	31
<b>4.3 Contamination of Food or Water Supplies .....</b>	32
<b>4.3.1 Incident Characteristics .....</b>	32
<b>4.3.2 Nature of Contamination .....</b>	33
<b>4.4 Improvised Nuclear Device .....</b>	33
<b>4.4.1 Incident Characteristics .....</b>	33
<b>4.4.2 Nature of Contamination .....</b>	35

<b>4.5</b>	Nuclear Reactor Incident .....	35
<b>4.5.1</b>	Incident Characteristics .....	36
<b>4.5.2</b>	Nature of Contamination .....	37
<b>4.6</b>	Large-Scale Fires and Incidents .....	37
<b>4.6.1</b>	Incident Characteristics .....	37
<b>4.6.2</b>	Nature of Contamination .....	38
<b>4.7</b>	Sealed Radioactive Source Incidents .....	38
<b>4.7.1</b>	Incident Characteristics .....	39
<b>4.7.2</b>	Nature of Contamination .....	39
<b>4.8</b>	Summary .....	40
<b>5.</b>	<b>Coordination with the Incident Command System</b> .....	41
<b>5.1</b>	Introduction .....	41
<b>5.2</b>	Incident Command System .....	43
<b>5.3</b>	Hospital Incident Command System .....	46
<b>5.4</b>	Coordination Between Incident Command System and Hospital Incident Command System .....	48
<b>5.5</b>	Communicating Information from the Scene to the Hospitals and from the Hospitals to the Scene .....	48
<b>6.</b>	<b>Radiological Triage and Screening Guidance</b> .....	53
<b>6.1</b>	General Guidance for Emergency Responders .....	53
<b>6.1.1</b>	Selecting an Appropriate Radiation Survey Instrument .....	54
<b>6.1.2</b>	Presurvey Radiation Survey Instrument Checks .....	55
<b>6.1.3</b>	Surveying for Radioactive Contamination .....	56
<b>6.2</b>	Radiological Triage and Screening Procedures .....	56
<b>6.3</b>	Initial Screening at Scene .....	57
<b>6.4</b>	Initial Screening at Hospital .....	60
<b>6.5</b>	Mass Screening Following the Emergency Phase .....	61
<b>6.6</b>	Biodosimetry .....	61
<b>7.</b>	<b>Clinical Decision Guide: Concept and Use</b> .....	65
<b>7.1</b>	Clinical Decision Guide Concept .....	65
<b>7.2</b>	Clinical Use of the Clinical Decision Guide .....	68
<b>7.2.1</b>	Decision-Making Process .....	68
<b>7.2.2</b>	Use of the CDG Tables .....	69
<b>7.2.3</b>	Use of a Single-Void Urine Sample Collected During the First 24 h .....	70
<b>7.2.4</b>	Using the CDG with an Intake of Multiple Radionuclides .....	70
<b>7.2.5</b>	Determining an Intake for Times More than 24 h in the Past .....	71
<b>7.2.6</b>	Special Considerations for Uranium CDGs .....	73
<b>7.3</b>	Americium-241: Clinical Decision Guide Fact Sheet .....	78

<b>7.4</b>	Cesium-137: Clinical Decision Guide Fact Sheet .....	79
<b>7.5</b>	Cobalt-60: Clinical Decision Guide Fact Sheet .....	80
<b>7.6</b>	Iodine-131: Clinical Decision Guide Fact Sheet .....	82
<b>7.7</b>	Iridium-192: Clinical Decision Guide Fact Sheet .....	84
<b>7.8</b>	Plutonium-238: Clinical Decision Guide Fact Sheet .....	85
<b>7.9</b>	Plutonium-239: Clinical Decision Guide Fact Sheet .....	86
<b>7.10</b>	Radium-226: Clinical Decision Guide Fact Sheet .....	88
<b>7.11</b>	Strontium-90: Clinical Decision Guide Fact Sheet .....	89
<b>7.12</b>	Uranium: Clinical Decision Guide and Nephrotoxicity Fact Sheet .....	90
<b>7.12.1</b>	Treatment Based on Radiological Properties of Uranium (CDG) .....	90
<b>7.12.2</b>	Treatment Based on Nephrotoxic Properties of Uranium .....	91
<b>7.13</b>	Clinical Decision Guide Technical Details .....	93
<b>7.13.1</b>	Noniodine Radionuclides .....	93
<b>7.13.2</b>	Iodine Radionuclides .....	94
<b>7.13.3</b>	Uranium Mass and Activity Calculations .....	94
<b>8.</b>	<b>Rapid Determination of Internal Contamination</b> .....	96
<b>8.1</b>	Rapid Identification of Radionuclide(s) Involved .....	97
<b>8.2</b>	Screening for External Contamination .....	98
<b>8.3</b>	Direct ( <i>in vivo</i> ) Screening for Internal Contamination .....	99
<b>8.3.1</b>	Detection of Internal Contamination by Direct Measurement .....	99
<b>8.3.1.1</b>	GM Survey Meter.....	101
<b>8.3.1.2</b>	Whole-Body and Lung Counters .....	101
<b>8.3.2</b>	Hospital Equipment for the Detection and Quantitation of Radionuclides .....	103
<b>8.3.2.1</b>	GM Survey Meter.....	103
<b>8.3.2.2</b>	Nuclear Medicine Thyroid-Uptake Probe.....	104
<b>8.3.2.3</b>	Portal Monitors.....	105
<b>8.3.2.4</b>	Nuclear Medicine Gamma Camera .....	106
<b>8.3.2.5</b>	Pulse-Height Analyzer and Radionuclide Windows .....	107
<b>8.3.3</b>	Measuring Internal Contamination with Hospital Equipment .....	110
<b>8.3.3.1</b>	Using GM Survey Meters to Assess Internal Contamination with Certain Gamma-Emitting Radionuclides .....	110
<b>8.3.3.2</b>	Using a Gamma Camera or Thyroid- Uptake Probe to Assess Internal Contamination with Certain Gamma- Emitting Radionuclides .....	110

8.4	8.3.4 Wound Monitoring .....	112
8.4	Indirect ( <i>in vitro</i> ) Determination of Internal Contamination .....	113
8.4.1	Nasal Swabs .....	113
8.4.2	Urine Samples .....	114
8.4.3	Blood Samples .....	115
8.4.4	Fecal Samples .....	116
8.4.5	Analysis of Indirect Bioassay Samples .....	116
8.5	Rapid Screening of Persons to Identify Radionuclide Intakes that Exceed the Clinical Decision Guide .....	117
9.	<b>Medical Management of Internally-Contaminated Persons</b> .....	121
9.1	Introduction .....	121
9.2	General Clinical Guidance for the Treatment of Internal Contamination .....	122
9.3	Making Requests for Radiological Countermeasures ..	124
9.4	Medical Management Decisions for Potentially-Contaminated Persons .....	125
9.4.1	Triage .....	125
9.4.2	Prioritizing Children and Pregnant Women ..	126
9.4.3	Medical Decisions During the Early Phases of a Radiation Incident .....	127
9.4.4	Choice of Décorporation Therapy for Internally-Deposited Radionuclides .....	128
9.4.5	Self-Treatment .....	129
9.4.6	Contaminated Wound Management .....	129
9.4.7	Using DTPA on Radionuclide-Contaminated Wounds .....	130
9.5	Medical Management of an Americium-241 Intake ..	131
9.5.1	Overview .....	131
9.5.2	Treatment .....	131
9.5.3	Medical Follow-Up After Treatment .....	134
9.6	Medical Management of a Cesium-137 Intake .....	134
9.6.1	Overview .....	134
9.6.2	Treatment .....	135
9.6.3	Medical Follow-Up After Treatment .....	135
9.7	Medical Management of a Cobalt-60 Intake .....	135
9.7.1	Overview .....	135
9.7.2	Treatment .....	138
9.7.3	Medical Follow-Up After Treatment .....	138
9.8	Medical Management of an Iodine-131 Intake .....	138
9.8.1	Overview .....	138
9.8.2	Treatment .....	140
9.8.3	Medical Follow-Up After Treatment .....	140

CONTENTS / ix

<b>9.9</b>	Medical Management of an Iridium-192 Intake .....	140
<b>9.9.1</b>	Overview .....	140
<b>9.9.2</b>	Treatment .....	145
<b>9.9.3</b>	Medical Follow-Up After Treatment .....	145
<b>9.10</b>	Medical Management of a Plutonium-238 or -239 Intake .....	145
<b>9.10.1</b>	Overview .....	145
<b>9.10.2</b>	Treatment .....	146
<b>9.10.3</b>	Medical Follow-Up After Treatment .....	146
<b>9.11</b>	Medical Management of a Radium-226 Intake .....	146
<b>9.11.1</b>	Overview .....	146
<b>9.11.2</b>	Treatment .....	147
<b>9.11.3</b>	Medical Follow-Up After Treatment .....	147
<b>9.12</b>	Medical Management of a Strontium-90 Intake .....	147
<b>9.12.1</b>	Overview .....	147
<b>9.12.2</b>	Treatment .....	147
<b>9.12.3</b>	Medical Follow-Up After Treatment .....	150
<b>9.13</b>	Medical Management of a Uranium-235 or -238 Intake .....	150
<b>9.13.1</b>	Overview .....	150
<b>9.13.2</b>	Treatment .....	153
<b>9.13.3</b>	Medical Follow-Up After Treatment .....	153
<b>10. Social, Psychological and Communication Issues Associated with Screening and Monitoring a Population .....</b> 155		
<b>10.1</b>	Introduction .....	155
<b>10.2</b>	General Approach .....	156
<b>10.3</b>	Program and Center Names .....	156
<b>10.4</b>	Enlisting the Public as a Partner .....	156
<b>10.5</b>	Communicating with Members of the Public .....	157
<b>10.6</b>	Proactive Approach .....	157
<b>10.7</b>	Information Hotlines .....	158
<b>10.8</b>	Special Services, Approaches and Materials for Children .....	159
<b>10.9</b>	Persons with Reproductive and Fertility Concerns .....	160
<b>10.10</b>	Other Special Populations .....	161
<b>10.11</b>	Addressing Staff Concerns and Information Needs .....	161
<b>10.12</b>	Staff Support .....	162
<b>10.13</b>	Training Exercises .....	162
<b>10.14</b>	Understanding and Addressing Responder Concerns and Information Needs .....	163
<b>11. Long-Term Follow-Up of Individuals .....</b> 165		
<b>11.1</b>	Identification of the Population to be Followed .....	165
<b>11.2</b>	Classification of Persons to be Monitored or Followed .....	168
<b>11.3</b>	Follow-Up Procedures .....	171

<b>12. Scalability .....</b>	172
<b>13. Assessment of Current Capacity in the United States to Perform Population Screening, Decontamination and Monitoring for Internal Contamination .....</b>	180
<b>13.1 Availability of Equipment and Resources .....</b>	181
<b>13.2 Laboratory Capabilities .....</b>	182
<b>13.3 Training Needs on Use of Equipment .....</b>	183
<b>13.4 Radiation Volunteers to Support Population Screening</b>	185
<b>13.5 Biodosimetry .....</b>	186
<b>13.6 Conclusions .....</b>	187
<b>14. Conclusions and Recommendations .....</b>	188
<b>14.1 Recommendations for Planning .....</b>	188
<b>14.2 Recommendations Related to Screening and Treatment of a Population for Internal Contamination .....</b>	189
<b>14.3 Recommendations for Additional Work .....</b>	190
<b>Appendix A. Radiological Properties of Radionuclides Considered in this Report .....</b>	192
<b>Appendix B. How to Perform a Radiation Survey for Contamination: Instructions for Workers .....</b>	202
<b>B.1 Screening Survey .....</b>	202
<b>B.2 Complete Whole-Body Survey .....</b>	203
<b>B.3 Most Common Mistakes Made During the Survey .....</b>	204
<b>Appendix C. How to Distinguish Between Alpha, Beta and Gamma Radiation Using a Geiger-Muller Survey Meter .....</b>	205
<b>C.1 Determining the Presence of an Alpha-Emitting Radionuclide Using Only a Geiger-Muller Survey Meter .....</b>	206
<b>C.2 Determining the Presence of Strontium-90 (or other pure beta emitters) Using a Pancake Geiger-Muller Survey Meter .....</b>	206
<b>Appendix D. Survey and Registry Forms .....</b>	208
<b>D.1 Contamination Survey Sheet .....</b>	208
<b>D.2 Registry Form .....</b>	211
<b>D.3 ATSDR Rapid Response Registry Survey Form ATSDR Rapid Response Registry Survey Form .....</b>	214
<b>Appendix E. How to Perform Decontamination at Home ..</b>	216

<b>Appendix F. Using Geiger-Muller Survey Meters to Assess Internal Contamination for Selected Gamma-Emitting Radionuclides .....</b>	218
<b>Appendix G. Collection and Preparation of Biological Samples for Radioanalysis .....</b>	228
<b>G.1 Urine Samples .....</b>	228
<b>G.2 Main Collection Issues .....</b>	228
<b>Appendix H. Shipping of Biological Samples .....</b>	231
<b>H.1 Introduction .....</b>	231
<b>H.2 Regulatory Information: Brief Summary .....</b>	231
<b>H.3 Definitions .....</b>	232
<b>H.4 General Shipping Guidelines for Clinical, Diagnostic and Exempt Biological Samples .....</b>	232
<b>H.5 Specific Shipping Guidelines for Clinical, Diagnostic and Exempt Biological Samples .....</b>	234
<b>H.6 Website Links for Some Commercial Shippers .....</b>	234
<b>Appendix I. Population Screening and Monitoring Implications of Two Urban Contamination Incidents ..</b>	235
<b>I.1 Background .....</b>	235
<b>I.2 Overview of Two Cases .....</b>	236
<b>I.2.1 Goiânia, Brazil .....</b>	236
<b>I.2.2 London, United Kingdom .....</b>	236
<b>Appendix J. Pregnancy Categories for Drug Use .....</b>	238
<b>Appendix K. Emergency Phone Numbers for Government Officials to Request Assistance Following a Radiological or Nuclear Incident .....</b>	239
<b>Glossary .....</b>	240
<b>Abbreviations and Acronyms .....</b>	247
<b>References .....</b>	248
<b>The NCRP .....</b>	264
<b>NCRP Publications .....</b>	273